Role of BET proteins in castration-resistant prostate cancer
Copyright policy )Role of BET proteins in castration-resistant prostate cancer
Castration resistant prostate cancer (CRPC) is a deadly disease with few therapeutic options once patients become resistant to second generation drugs targeting the AR-transcriptional program. The BET-BRD readers of chromatin are key regulators of AR-, ERG-, and c-Myc-mediated transcription in CRPC. BET-BRD inhibitors have demonstrated pre-clinical efficacy in models of CRPC and are currently being evaluated in several clinical trials. These novel drugs have the potential to transform the way we treat CRPC in the near future.
- Howard Hughes Medical Institute United States
- University of Michigan–Flint United States
- Michigan Center for Translational Pathology United States
- University of Michigan–Ann Arbor United States
Male, Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen, Animals, Humans, Nuclear Proteins, Antineoplastic Agents, Signal Transduction, Transcription Factors
Male, Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen, Animals, Humans, Nuclear Proteins, Antineoplastic Agents, Signal Transduction, Transcription Factors
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).16 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!